Your institution may have access to this item. Find your institution then sign in to continue.
Title
FDA Approves Vemurafenib for Treatment of Metastatic Melanoma.
Abstract
The article reports on the approval of vemurafenib by the U.S. Food and Drug Administration (FDA) for treating metastatic melanoma. The drug also known as PLX4032, targets patients whose tumors express the BRAF V600E gene mutation. It states vemurafenib blocks a mutated protein in the cancer. It states prior to vemurafenib, dacarbanzine was the only chemotherapeutic agent approved by the FDA.